# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

> **NCT02808793** · PHASE1 · COMPLETED · sponsor: **Allakos Inc.** · enrollment: 25 (actual)

## Conditions studied

- Indolent Systemic Mastocytosis

## Interventions

- **DRUG:** AK002

## Key facts

- **NCT ID:** NCT02808793
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808793, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02808793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*